Drag a card by its title · ⚙ to size, swap or remove

The company

MKS Inc.

MKSI · Nasdaq

Health CareLife-science toolsNot moving yetAI

MKSI stood above a rising 150-day average in 43 of the last 52 weekly readings, and has been out of that trend for the last 9 weeks. It is 27.0% below that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 9
Industry in uptrend: 52% +4 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $86.9M
Officials’ trades on record: 8
Institutions holding: 724 (+152)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 43 of 52 weeks.

17 Apr – 16 Oct

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

8 disclosed lines: House 5, Senate 3, executive 0; 3 people.

Who	Did	Amount	Traded
Lisa C. McClain House: U.S. House ClerkMI09	soldspouse	$1k–$15k	31 Oct 2025filed 21 Nov 2025
Lisa C. McClain House: U.S. House ClerkMI09	soldspouse	$1k–$15k	30 Oct 2025filed 21 Nov 2025
Lisa C. McClain House: U.S. House ClerkMI09	boughtspouse	$1k–$15k	30 Oct 2025filed 21 Nov 2025
Lisa C. McClain House: U.S. House ClerkMI09	boughtspouse	$1k–$15k	4 Aug 2025filed 12 Sep 2025
Tommy Tuberville Senate: U.S. Senate eFDSenator	soldjoint	$1k–$15k	3 Apr 2023filed 12 May 2023
Tommy Tuberville Senate: U.S. Senate eFDSenator	soldjoint	$1k–$15k	3 Apr 2023filed 11 May 2023
Tommy Tuberville Senate: U.S. Senate eFDSenator	boughtjoint	$1k–$15k	30 Mar 2022filed 8 Apr 2022
Van Taylor House: U.S. House ClerkTX03	sold	$1k–$15k	25 Mar 2019filed 15 Apr 2019

Insiders

Buy orders, 12 months0

Sale orders, 12 months34

Buyers · sellers0 · 13

Who	Did	Shares	Traded
Elizabeth MoraDirector	sold	300at $250.96	1 Sep 2026filed 2 Sep 2026
John Tseng-Chung LeePresident & CEO	sold	10,000at $302.01	14 Aug 2026filed 17 Aug 2026
John Edward WilliamsEVP & GM, PSD	sold	457at $288.31	3 Aug 2026filed 4 Aug 2026
James Alan SchreinerEVP & COO	sold	2,471at $345.52	12 Jun 2026filed 16 Jun 2026
James Alan SchreinerEVP & COO	sold	812at $346.41	12 Jun 2026filed 16 Jun 2026
James Alan SchreinerEVP & COO	sold	217at $347.00	12 Jun 2026filed 16 Jun 2026
James Alan SchreinerEVP & COO	sold	781at $317.42	10 Jun 2026filed 11 Jun 2026
Michelle M. McCarthySVP & Chief Accounting Officer	sold	2,434at $315.23	5 Jun 2026filed 8 Jun 2026
Elizabeth MoraDirector	sold	300at $318.02	1 Jun 2026filed 2 Jun 2026
David Philip HenryEVP, Global Str Mktg & GM, MSD	sold	6,000at $314.43	1 Jun 2026filed 2 Jun 2026
Gerald G. ColellaDirector	sold	464at $330.38	27 May 2026filed 28 May 2026
Gerald G. ColellaDirector	sold	8,210at $331.45	27 May 2026filed 28 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders724+152 on the quarter

New · exited209 · 58

Reported value$29.2B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
BlackRock, Inc.added · filed 7 Aug 2026	6,930,030$3.1B	+288,300+4.3%
Invesco Ltd.added · filed 14 Aug 2026	4,661,664$2.1B	+940,205+25.3%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026	3,707,327$1.6B	+21,834+0.6%
JPMORGAN CHASE & COnew · filed 12 Aug 2026	3,373,844$1.4B	+3,373,844
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	3,049,560$1.4B	+35,359+1.2%
STATE STREET CORPadded · filed 7 Aug 2026	2,134,663$949.4M	+76,931+3.7%
Point72 Asset Management, L.P.added · filed 14 Aug 2026	1,996,843$888.2M	+386,512+24.0%
Capital International Investorsreduced · filed 12 Aug 2026	1,915,187$851.9M	-53,583−2.7%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026	1,539,072$686.6M	-2470.0%
FMR LLCreduced · filed 13 Aug 2026	1,499,498$667.0M	-434,345−22.5%

31 Mar 2023 – 30 Jun 2026

News

No headline names it lately.

Everyone who traded it

Elizabeth Mora Director · last 1 Sep 20260 · 48

Renee Martel Donlan EVP, GC & CCO · last 17 Aug 20260 · 0

John Tseng-Chung Lee President & CEO · last 14 Aug 20263 · 23

John Edward Williams EVP & GM, PSD · last 3 Aug 20260 · 3

James Alan Schreiner EVP & COO · last 12 Jun 20260 · 6

Michelle M. McCarthy SVP & Chief Accounting Officer · last 5 Jun 20260 · 2

David Philip Henry EVP, Global Str Mktg & GM, MSD · last 1 Jun 20261 · 6

Gerald G. Colella Director · last 27 May 20261 · 58

Joseph B. Donahue Director · last 27 May 20260 · 1

Ramakumar Mayampurath EVP & CFO · last 22 May 20260 · 1

Peter Cannone III Director · last 18 May 20261 · 2

Jacqueline F. Moloney Director · last 14 May 20260 · 22

Same industry

OABI OmniAbLeading+65%

TXG 10x GenomicsLeading+60%

AVTR AvantorLeading+47%

ILMN IlluminaLeading+44%

RVTY RevvityLeading+37%

CRL Charles River Laboratories InternationalLeading+35%

MASS 908 DevicesLeading+31%

IQV IQVIA HoldingsLeading+27%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202546.7%

Operating profit marginFY 2025 · to 31 Dec 202513.4%

Free cash flow marginFY 2025 · to 31 Dec 202512.6%

Return on capital employedFY 2025 · to 31 Dec 20256.7%

Cash conversionFY 2025 · to 31 Dec 2025219%

Debt to equityFY 2025 · to 31 Dec 20251.55×

Interest coverFY 2025 · to 31 Dec 20252.49×

Research spendFY 2025 · to 31 Dec 20257.6%

Dividend growthFY 2025 · to 31 Dec 2025300%

Share count trendFY 2025 · to 17 Feb 20260.1%

Cash and equivalentsFY 2025 · to 31 Dec 2025$418.0M

Free cash flowFY 2025 · to 31 Dec 2025$497.0M

Analyst forecasts

No analyst forecasts yet.